BRPI0718339A2 - Composto, composição, composição farmacêutica e processo de fabricação de tanato de rasagilina - Google Patents

Composto, composição, composição farmacêutica e processo de fabricação de tanato de rasagilina

Info

Publication number
BRPI0718339A2
BRPI0718339A2 BRPI0718339-9A2A BRPI0718339A BRPI0718339A2 BR PI0718339 A2 BRPI0718339 A2 BR PI0718339A2 BR PI0718339 A BRPI0718339 A BR PI0718339A BR PI0718339 A2 BRPI0718339 A2 BR PI0718339A2
Authority
BR
Brazil
Prior art keywords
composition
tanate
rasagiline
manufacturing process
pharmaceutical
Prior art date
Application number
BRPI0718339-9A2A
Other languages
English (en)
Inventor
Anton Frenkel
Tamas Koltai
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BRPI0718339A2 publication Critical patent/BRPI0718339A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
BRPI0718339-9A2A 2006-12-14 2007-12-13 Composto, composição, composição farmacêutica e processo de fabricação de tanato de rasagilina BRPI0718339A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87503806P 2006-12-14 2006-12-14
PCT/US2007/025516 WO2008076315A1 (en) 2006-12-14 2007-12-13 Tannate salt of rasagiline

Publications (1)

Publication Number Publication Date
BRPI0718339A2 true BRPI0718339A2 (pt) 2014-02-18

Family

ID=39536617

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0718339-9A2A BRPI0718339A2 (pt) 2006-12-14 2007-12-13 Composto, composição, composição farmacêutica e processo de fabricação de tanato de rasagilina

Country Status (23)

Country Link
US (1) US7547806B2 (pt)
EP (1) EP2101570B1 (pt)
JP (1) JP5356248B2 (pt)
KR (1) KR101077835B1 (pt)
CN (1) CN101600346B (pt)
AU (1) AU2007334493B2 (pt)
BR (1) BRPI0718339A2 (pt)
CA (1) CA2672452C (pt)
DK (1) DK2101570T3 (pt)
EA (1) EA016843B1 (pt)
ES (1) ES2420124T3 (pt)
HR (1) HRP20130396T1 (pt)
IL (1) IL198984A (pt)
MX (1) MX2009006252A (pt)
NO (1) NO20092609L (pt)
NZ (1) NZ577623A (pt)
PL (1) PL2101570T3 (pt)
PT (1) PT2101570E (pt)
RS (1) RS52784B (pt)
SI (1) SI2101570T1 (pt)
UA (1) UA97382C2 (pt)
WO (1) WO2008076315A1 (pt)
ZA (1) ZA200903904B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060018957A1 (en) * 2004-07-26 2006-01-26 Lerner E I Pharmaceutical dosage forms including rasagiline
ES2371883T3 (es) * 2004-11-24 2012-01-11 Teva Pharmaceutical Industries Ltd. Composiciones de rasagilina de disgregación oral.
RS52867B (sr) * 2005-02-17 2013-12-31 Teva Pharmaceutical Industries Ltd. Kombinovana terapija glatiramer acetatom i razagilinom za lečenje multiple skleroze
US7815942B2 (en) * 2005-02-23 2010-10-19 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
US7491847B2 (en) * 2005-11-17 2009-02-17 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
US8809310B2 (en) * 2006-02-21 2014-08-19 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
AU2007235517B2 (en) 2006-04-03 2013-01-31 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Restless Legs Syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
UA97382C2 (ru) 2006-12-14 2012-02-10 Тева Фармасьютікл Індастріз, Лтд. Таннат разагилина
AU2007334428B2 (en) * 2006-12-14 2014-05-29 Teva Pharmaceutical Industries, Ltd. Crystalline solid rasagiline base
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
AU2009258120B2 (en) * 2008-06-10 2014-11-27 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
EP2296462A4 (en) * 2008-06-13 2011-06-15 Teva Pharma RASAGILINE FOR INFLUENCING MORBUS PARKINSON
NZ589547A (en) 2008-06-19 2013-03-28 Teva Pharma Dried rasagiline base having a water content less than 0.5 % by weight
JP2011525489A (ja) * 2008-06-19 2011-09-22 テバ ファーマシューティカル インダストリーズ リミティド ラサリジン塩基の精製方法
EP2218444A3 (en) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
US20100189790A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
PT2451771E (pt) 2009-07-09 2014-09-19 Ratiopharm Gmbh Sais de rasagilina e suas preparações farmacêuticas
EP2325159A1 (en) 2009-11-24 2011-05-25 LEK Pharmaceuticals d.d. Novel salts of rasagiline
WO2011087791A1 (en) * 2009-12-22 2011-07-21 Teva Pharmaceutical Industries Ltd. 3-keto-n-propargyl-1-aminoindan
WO2011080589A2 (en) 2009-12-30 2011-07-07 Actavis Group Ptc Ehf Solid state forms of rasagiline salts
WO2011095985A2 (en) * 2010-02-02 2011-08-11 Glenmark Generics Limited Rasagiline salts and processes for the preparation thereof
RU2587330C2 (ru) 2010-07-27 2016-06-20 Тева Фармасьютикал Индастриз Лтд. Применение разагилина для лечения обонятельной дисфункции
WO2012015946A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Dispersion of rasagiline citrate
CA2851433A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-methyl-propargyl-aminoindan
BR112014008555A2 (pt) 2011-10-10 2017-04-18 Teva Pharma r(+)-n-formil-propargil-aminoindano
WO2013139387A1 (en) 2012-03-21 2013-09-26 Synthon Bv Stabilized pharmaceutical compositions comprising rasagiline salts
AR092168A1 (es) 2012-08-17 2015-03-25 Teva Pharma Formulaciones parenterales de rasagilina
WO2015160678A1 (en) 2014-04-17 2015-10-22 Merck Sharp & Dohme Corp. Sitagliptin tannate complex
CN107125438A (zh) * 2016-02-29 2017-09-05 湖南晶天科技实业有限公司 一种饲料添加剂鞣酸生物碱及其制备方法以及一种复合添加剂和一种饲料
TW201818969A (zh) * 2016-10-19 2018-06-01 日商帝化製藥股份有限公司 在生體內之藥物溶出控制用組成物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
US5663415A (en) * 1996-06-28 1997-09-02 Jame Fine Chemicals, Inc. Process for preparing antihistamine tannates
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
CA2275425C (en) 1996-12-18 2009-08-04 Michael Chorev Aminoindan derivatives
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
FR2771102B1 (fr) * 1997-11-14 2000-12-15 Biocoral Inc Procede pour induire la differenciation osteoblastique de cellules de tissu adipeux extramedullaire humain
WO2002005745A2 (en) * 2000-07-14 2002-01-24 Cadila Pharmaceuticals Limited The process of manufacturing pharmaceutical grade tannates
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US6869618B2 (en) 2001-04-10 2005-03-22 Kiel Laboratories, Inc. Process for preparing tannate liquid and semi-solid dosage forms
SI1567152T1 (sl) 2002-11-15 2013-10-30 Teva Pharmaceutical Industries Ltd. Uporaba rasagilina z riluzolom za zdravljenje amiotrofične lateralne skleroze
US20040157784A1 (en) * 2003-02-10 2004-08-12 Jame Fine Chemicals, Inc. Opiod tannate compositions
WO2004093867A2 (en) * 2003-03-25 2004-11-04 Kiel Laboratories, Inc. Phenolic acid salts of gabapentin in liquid and/or semi-solid dosage forms and methods of use
ATE450535T1 (de) * 2003-09-03 2009-12-15 Glaxo Group Ltd Neues verfahren zur herstellung von pleuromutilinderivaten
WO2005025573A1 (en) * 2003-09-05 2005-03-24 P3 Laboratories, Inc. Compositions and methods for treating pain
US20050202050A1 (en) * 2004-03-12 2005-09-15 Kiel Jeffrey S. Single tank process for preparing tannate liquid and semi-solid dosage forms
US20060018957A1 (en) 2004-07-26 2006-01-26 Lerner E I Pharmaceutical dosage forms including rasagiline
WO2006057912A2 (en) 2004-11-24 2006-06-01 Teva Pharmaceutical Industries, Ltd. Rasagiline orally disintegrating compositions
US7815942B2 (en) 2005-02-23 2010-10-19 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
US7491847B2 (en) 2005-11-17 2009-02-17 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
US8809310B2 (en) 2006-02-21 2014-08-19 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
AU2007235517B2 (en) 2006-04-03 2013-01-31 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Restless Legs Syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
UA97382C2 (ru) 2006-12-14 2012-02-10 Тева Фармасьютікл Індастріз, Лтд. Таннат разагилина
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff

Also Published As

Publication number Publication date
KR20090088433A (ko) 2009-08-19
KR101077835B1 (ko) 2011-10-28
US20080146676A1 (en) 2008-06-19
EP2101570B1 (en) 2013-02-13
CN101600346A (zh) 2009-12-09
PT2101570E (pt) 2013-05-17
CN101600346B (zh) 2013-08-21
MX2009006252A (es) 2009-10-13
HRP20130396T1 (en) 2013-06-30
DK2101570T3 (da) 2013-05-27
JP5356248B2 (ja) 2013-12-04
UA97382C2 (ru) 2012-02-10
AU2007334493A1 (en) 2008-06-26
EA200970580A1 (ru) 2009-12-30
IL198984A (en) 2013-03-24
RS52784B (sr) 2013-10-31
EP2101570A4 (en) 2011-04-06
AU2007334493B2 (en) 2010-12-02
EP2101570A1 (en) 2009-09-23
CA2672452A1 (en) 2008-06-26
JP2010513280A (ja) 2010-04-30
NO20092609L (no) 2009-09-04
EA016843B1 (ru) 2012-07-30
HK1129277A1 (en) 2009-11-27
IL198984A0 (en) 2010-02-17
ES2420124T3 (es) 2013-08-22
US7547806B2 (en) 2009-06-16
NZ577623A (en) 2011-05-27
PL2101570T3 (pl) 2013-07-31
SI2101570T1 (sl) 2013-06-28
CA2672452C (en) 2012-07-03
ZA200903904B (en) 2010-08-25
WO2008076315A1 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
BRPI0720068A2 (pt) Processo para preparar nanocápsulas, produto, nanocápsulas e composição
BRPI0818533A2 (pt) composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0812481A2 (pt) Composição aquosa, processo para a fabricação da composição aquosa, uso da composição aquosa, e, processo para a produção de epicloridrina
BRPI0821445A2 (pt) Folha, processo de fabricação de uma folha, e, artigo
BRPI0821801A2 (pt) Zeólito e processo de preparação de um zeólito.
BRPI0809681A2 (pt) processo para fabricação de polímeros
BRPI0718386A2 (pt) Processo para preparação de catalisadores.
BRPI0718440A2 (pt) Processo de preparo de halogenetos de n-alquinaltrexona
BRPI0911767A2 (pt) Processo, e, composto.
BRPI0720174A2 (pt) Processo para modificação da resistência de plantas a insetos através da utilização da técnica de rnai
PT2201156E (pt) Composição biocombustível e processo de fabrico
BRPI0718075A2 (pt) Processo de hidrogenação
BRPI0819518A2 (pt) "dispositivo, dispositivo de eletrodiálise e processo de eletrodiálise"
BRPI0914221A2 (pt) processo, e, composto
EP1927603A4 (en) COMPOSITION OF SYRUP, RESIN MORTAR COMPOSITION AND METHOD OF APPLICATION
BRPI0720530A2 (pt) Partícula, processo para preparar a partícular, e, composição
BRPI0717897A2 (pt) Processo para produção de ácido acrílico, aparelho para produção de ácido acrílico e composição para produção de ácido acrílico
BRPI0815922A2 (pt) Artigo, composição, e, método.
FI20070991A0 (fi) Lasituote, tuotteen käyttö ja valmistusmenetelmä
BRPI0814448A2 (pt) processo de produção de trazodona e cloridrato de trazodona, trazodona e cloridrato de trazodona, e, composição farmacêutica
BRPI0812900A2 (pt) Processo de granulação e dispositivo correlato.
BRPI0816237A2 (pt) Processo de ciclopropanação
BRPI0718999A2 (pt) Pirazois substituídos, composições que os contêm, processo de produção e utilização
BRPI0622063A2 (pt) Processo para a fabricação de pneumático, e, estrutura de talão de pneumático.
BRPI0821471A2 (pt) Processo para a preparação de isomalto-oligossacarídeo hidrogenado, e, xarope de isomalto-oligossacarídeo hidrogenado

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]